BE2012C001I2 - - Google Patents

Info

Publication number
BE2012C001I2
BE2012C001I2 BE2012C001C BE2012C001C BE2012C001I2 BE 2012C001 I2 BE2012C001 I2 BE 2012C001I2 BE 2012C001 C BE2012C001 C BE 2012C001C BE 2012C001 C BE2012C001 C BE 2012C001C BE 2012C001 I2 BE2012C001 I2 BE 2012C001I2
Authority
BE
Belgium
Prior art keywords
human
antibodies
infections
conditions
methods
Prior art date
Application number
BE2012C001C
Other languages
French (fr)
Original Assignee
Squibb & Sons Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Llc filed Critical Squibb & Sons Llc
Publication of BE2012C001I2 publication Critical patent/BE2012C001I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)

Abstract

The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
BE2012C001C 1999-08-24 2012-01-09 BE2012C001I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15045299P 1999-08-24 1999-08-24
EP00959399A EP1212422B1 (en) 1999-08-24 2000-08-24 Human ctla-4 antibodies and their uses
PCT/US2000/023356 WO2001014424A2 (en) 1999-08-24 2000-08-24 Human ctla-4 antibodies and their uses

Publications (1)

Publication Number Publication Date
BE2012C001I2 true BE2012C001I2 (en) 2019-10-16

Family

ID=22534598

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C001C BE2012C001I2 (en) 1999-08-24 2012-01-09

Country Status (22)

Country Link
US (1) US6984720B1 (en)
EP (4) EP1792991A1 (en)
JP (4) JP4093757B2 (en)
KR (3) KR100942863B1 (en)
CN (2) CN1371416B (en)
AT (1) ATE354655T1 (en)
AU (3) AU784012B2 (en)
BE (1) BE2012C001I2 (en)
CA (2) CA2381770C (en)
CY (2) CY1107628T1 (en)
DE (2) DE60033530T2 (en)
DK (1) DK1212422T3 (en)
ES (1) ES2282133T3 (en)
FR (1) FR12C0004I2 (en)
HK (1) HK1048831A1 (en)
IL (3) IL148079A0 (en)
LU (1) LU91928I2 (en)
MX (1) MXPA02001911A (en)
NZ (1) NZ517202A (en)
PT (1) PT1212422E (en)
WO (1) WO2001014424A2 (en)
ZA (1) ZA200201190B (en)

Families Citing this family (961)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69938871D1 (en) * 1998-12-03 2008-07-17 Univ California Stimulating T cells against self antigens using CTLA-4 inhibiting agents
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CZ303703B6 (en) * 1998-12-23 2013-03-20 Pfizer Inc. Monoclonal antibody or fragment-binding antigen thereof, pharmaceutical composition in which the antibody or fragment is comprised, a cell line producing the antibody or fragment, process for preparing the antibody, isolated nucleic acid encoding hea
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1792991A1 (en) * 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2001066754A1 (en) * 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
AU2002255995A1 (en) 2001-03-30 2002-10-15 Avigenics, Inc. Avian lysozyme promoter
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AR038568A1 (en) * 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
AU2003234736B2 (en) * 2002-04-12 2008-09-25 E. R. Squibb & Sons, L.L.C. Methods of treatment using CTLA-4 antibodies
KR20050007375A (en) * 2002-05-02 2005-01-17 유니버시티 오브 코네티컷 헬스 센터 Use of heat shock proteins to enhance efficacy of antibody therapeutics
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2528254T3 (en) 2002-06-07 2015-02-05 Dyax Corp. Modified Kunitz domain polypeptides and their use to reduce ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
ES2654064T3 (en) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
ES2395014T3 (en) 2002-08-28 2013-02-07 Dyax Corp. Methods to preserve organs and tissues
CA2498264A1 (en) * 2002-09-09 2004-05-13 Nura, Inc. G protein coupled receptors and uses thereof
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
WO2004029069A2 (en) * 2002-09-30 2004-04-08 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
EP2330130B1 (en) 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
JP4739763B2 (en) 2002-12-16 2011-08-03 ゲンマブ エー／エス Human monoclonal antibody against interleukin 8 (IL-8)
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
RU2005131852A (en) 2003-03-14 2006-04-20 Уайт (Us) ANTIBODIES AGAINST THE HUMAN RECEPTOR IL-21 AND THEIR APPLICATION
ATE549359T1 (en) 2003-04-02 2012-03-15 Hoffmann La Roche ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND THEIR USES
NZ542866A (en) 2003-04-23 2009-07-31 Medarex Inc Compositions and methods for the therapy of inflammatory bowel disease
US7465446B2 (en) * 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
JP2007522096A (en) * 2003-06-06 2007-08-09 メディミューン，インコーポレーテッド Use of EphA4 and EphA4 modulators for cancer diagnosis, treatment, and prevention
AR046071A1 (en) 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1711207B1 (en) 2003-12-10 2012-11-28 Medarex, Inc. Interferon alpha antibodies and their uses
KR20130133302A (en) 2003-12-10 2013-12-06 메다렉스, 인코포레이티드 Ip-10 antibodies and their uses
PT2270045E (en) 2004-02-06 2015-04-08 Univ Massachusetts Antibodies against clostridium difficile toxins and uses thereof
AU2005225227A1 (en) * 2004-03-26 2005-10-06 Pfizer Products Inc. Uses of anti-CTLA-4 antibodies
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
AU2005258336A1 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to Fc gamma receptor I (CD64)
US7494779B2 (en) 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
ES2643237T3 (en) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Interferon alfa 1 receptor antibodies and their uses
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
JP2008522607A (en) * 2004-12-09 2008-07-03 ニューロ セラピューティクス エービー Dickkopfs and materials and methods related to neurogenesis
WO2006085518A1 (en) 2005-02-08 2006-08-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
SI1865986T1 (en) * 2005-03-08 2016-05-31 Pfizer Products Inc. Anti-ctla-4 antibody compositions
AU2012200203B2 (en) * 2005-03-08 2014-07-03 Pfizer Products Inc. Anti-CTLA-4 Antibody Compositions
AU2014240252B2 (en) * 2005-03-08 2016-10-06 Pfizer Products Inc Anti-CTLA-4 Antibody Compositions
WO2006099875A1 (en) 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
TW200700082A (en) * 2005-03-23 2007-01-01 Pfizer Prod Inc Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
US20060240006A1 (en) * 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
DE102005019845A1 (en) * 2005-04-28 2006-11-02 Li-Te Chin New human antibody capable of human CD152 (CTLA-4) binding or an antibody fragment, useful for diagnosing or treating human diseases caused by over- and/or under-expression of CD152
KR101339628B1 (en) * 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AU2006254902B8 (en) 2005-06-08 2012-08-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
KR101888321B1 (en) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
EP1904530A2 (en) * 2005-07-07 2008-04-02 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
EP2397497A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
CN100443503C (en) * 2005-07-18 2008-12-17 四川大学华西医院 Humanized CTLA-4 single chain antibody and human perforin path formed peptide P34 recombinant immunotoxin
NL1029605C2 (en) * 2005-07-25 2007-01-26 Li-Te Chin New human antibody capable of human CD152 (CTLA-4) binding or an antibody fragment, useful for diagnosing or treating human diseases caused by over- and/or under-expression of CD152
GB2429013C (en) 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
JP2009509510A (en) 2005-09-26 2009-03-12 メダレックス インコーポレーティッド Human monoclonal antibody against CD70
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US8906864B2 (en) * 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
AU2006311475A1 (en) * 2005-11-08 2007-05-18 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
KR20080090408A (en) 2005-11-30 2008-10-08 아보트 러보러터리즈 Anti-abeta; globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR101439828B1 (en) 2005-11-30 2014-09-17 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
WO2007067959A2 (en) 2005-12-07 2007-06-14 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
KR101446510B1 (en) 2005-12-08 2014-10-20 메다렉스, 엘.엘.시. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2007084672A2 (en) 2006-01-17 2007-07-26 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US9868961B2 (en) 2006-03-30 2018-01-16 The Regents Of The University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
JP5514539B2 (en) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP2010567A2 (en) 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antibody compositions and methods for treatment of neoplastic disease
US8524454B2 (en) * 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP2046834B9 (en) 2006-08-11 2013-04-10 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
AU2007292890A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
RS59005B1 (en) 2006-09-26 2019-08-30 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
JP2010504955A (en) 2006-09-28 2010-02-18 メルク セローノ ソシエテ アノニム Bonding molecule adhesion molecule C (JAM-C) binding compound and method of use thereof
ES2553553T3 (en) 2006-10-02 2015-12-10 E. R. Squibb & Sons, L.L.C. Human antibodies that bind to CXCR4 and their uses
DK2068922T3 (en) 2006-10-19 2012-10-08 Csl Ltd Anti-IL-13Ralfa1 antibodies and their applications
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
WO2008076560A2 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TWI447124B (en) 2006-12-01 2014-08-01 Medarex Llc Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
IN2009KN02404A (en) 2006-12-14 2015-08-07 Medarex Inc
DK2129396T3 (en) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antibodies to ErbB3 and uses thereof
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
CN101802015B (en) 2007-03-29 2015-05-06 根马布股份公司 Bispecific antibodies and methods for production thereof
FI20075278A0 (en) 2007-04-20 2007-04-20 Biotie Therapies Corp Novel completely human anti-VAP-1 monoclonal antibodies
EP4119579A1 (en) 2007-05-31 2023-01-18 Genmab A/S Stable igg4 antibodies
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
DK2769729T3 (en) 2007-09-04 2019-04-23 Compugen Ltd POLYPEPTIDES AND POLYNUCLEOTIDES AND APPLICATIONS THEREOF AS A PHARMACEUTICAL OBJECTIVE FOR THE PRODUCTION OF MEDICINAL PRODUCTS AND BIOTECHNOLOGICAL PRODUCTS
EP2033971A1 (en) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
TWI489993B (en) 2007-10-12 2015-07-01 Novartis Ag Compositions and methods of use for antibodies against sclerostin
DK2567709T3 (en) 2007-11-02 2018-03-12 Novartis Ag Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
JP5591712B2 (en) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス Antibodies against human NKG2D and uses thereof
US8449886B2 (en) * 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
KR20100115360A (en) 2008-02-05 2010-10-27 브리스톨-마이어스 스큅 컴퍼니 Alpha 5 - beta 1 antibodies and their uses
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
MX2010012579A (en) * 2008-05-29 2010-12-20 Squibb Bristol Myers Co Methods for predicting patient response to modulation of the co-stimulatory pathway.
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
UA105009C2 (en) 2008-08-05 2014-04-10 Новартіс Аг Compositions and methods for antibodies targeting complement protein c5
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
CA2744449C (en) * 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
EP2373687B1 (en) 2008-12-03 2016-10-26 Genmab A/S Igg4 antibody variants having modifications in the constant region
AU2009325878B2 (en) 2008-12-08 2014-01-16 Compugen Ltd. TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp Treatment of mucositis with kallikrein inhibitors
RU2636046C2 (en) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Modified antibodies composition, methods of production and application
ES2568509T3 (en) 2009-01-15 2016-04-29 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for the generation of monoclonal antibodies
EP2398494A4 (en) 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and methods of use thereof
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
PL2403878T3 (en) 2009-03-05 2017-12-29 E. R. Squibb & Sons, L.L.C. Fully human antibodies specific to cadm1
EP3831407A1 (en) 2009-04-08 2021-06-09 LipUm AB New methods for treatment of inflammatory diseases
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
BRPI1016055A2 (en) 2009-04-27 2016-05-10 Novartis Ag composition and methods of use for il-12 receptor beta-subunit specific therapeutic antibodies
BRPI1014522B8 (en) 2009-04-27 2021-05-25 Novartis Ag anti-actriib antibody or functional fragment, production process, pharmaceutical composition and uses
US20120101262A1 (en) 2009-06-25 2012-04-26 Bristol-Myers Squibb Company Protein purification by caprylic acid (octanoic acid) precipitation
PL2769737T3 (en) 2009-07-20 2017-08-31 Bristol-Myers Squibb Company Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
EP2480561B1 (en) 2009-09-23 2016-07-13 E. R. Squibb & Sons, L.L.C. Cation exchange chromatography
CN102740887B (en) 2009-09-30 2015-04-15 斯隆凯特林防癌纪念中心 Combination immunotherapy for the treatment of cancer
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
EP3255153A1 (en) 2009-11-17 2017-12-13 E. R. Squibb & Sons, L.L.C. Methods for enhanced protein production
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
CN102656190A (en) 2009-12-08 2012-09-05 雅培股份有限两合公司 Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
PT3459564T (en) 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins
CN103003307B (en) 2010-03-10 2017-08-11 根马布股份公司 Anti- c MEt monoclonal antibody
BR112012024166A2 (en) 2010-03-23 2022-09-27 Intrexon Corp VECTORS CONDITIONALLY EXPRESSING THERAPEUTIC PROTEINS, HOST CELLS COMPRISING THE VECTORS, AND USES THEREOF
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CA3079122A1 (en) 2010-03-26 2011-09-29 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
KR20130060223A (en) 2010-05-04 2013-06-07 메리맥 파마슈티컬즈, 인크. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
JP6082344B2 (en) 2010-05-27 2017-02-15 ゲンマブ エー／エス Monoclonal antibody against HER2 epitope
JP6320753B2 (en) 2010-05-27 2018-05-09 ゲンマブ エー／エス Monoclonal antibody against HER2
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
NO2582728T3 (en) 2010-06-15 2018-01-20
EP3327035A1 (en) 2010-06-22 2018-05-30 Precision Biologics Inc. Colon and pancreas cancer specific antigens and antibodies
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103298833B (en) 2010-08-14 2015-12-16 Abbvie公司 Amyloid beta associated proteins
UA114883C2 (en) 2010-08-20 2017-08-28 Новартіс Аг Antibodies for epidermal growth factor receptor 3 (her3)
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
ES2719624T3 (en) 2010-09-23 2019-07-11 Prec Biologics Inc Peptidomimetics of colon and pancreas cancer
CN104531812A (en) 2010-10-01 2015-04-22 现代治疗公司 Engineered nucleic acids and methods of use thereof
WO2012045703A1 (en) 2010-10-05 2012-04-12 Novartis Ag Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
KR101781546B1 (en) 2010-12-14 2017-09-26 내셔널 유니버시티 오브 싱가포르 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
KR102107695B1 (en) 2011-01-06 2020-05-07 다이액스 코포레이션 Plasma kallikrein binding proteins
US8906635B2 (en) 2011-02-28 2014-12-09 Northshore University Healthsystem Methods of diagnosing Clostridium difficile infection
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
JP2014511687A (en) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acid delivery and formulation
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
JP6177231B2 (en) 2011-04-20 2017-08-09 ゲンマブ エー／エス Bispecific antibody against HER2
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
CN103717619B (en) 2011-05-25 2018-11-13 因内特制药股份有限公司 Treat the anti-KIR antibodies of inflammation and autoimmune disease
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US9365651B2 (en) 2011-07-01 2016-06-14 Novartis Ag Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CN103945902B (en) 2011-08-30 2018-07-20 阿斯泰克斯制药公司 Decitabine derivative formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (en) 2011-10-03 2022-05-20 Modernatx Inc Nucleosides, nucleotides and modified nucleic acids, and their uses
RS53496B1 (en) * 2011-10-04 2015-02-27 Affiris Ag Method for detecting ass-specific antibodies in a biological sample
EP3653222A1 (en) 2011-10-14 2020-05-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
UY34487A (en) 2011-12-05 2013-07-31 Novartis Ag ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEIVER 3 (HER3)
BR112014013568A2 (en) 2011-12-05 2017-06-13 Novartis Ag epidermal growth factor 3 (her3) receptor antibodies directed to her3 domain ii
JP6336397B2 (en) 2011-12-14 2018-06-06 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Compositions and methods for diagnosing and treating iron-related disorders
US10118958B2 (en) 2011-12-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
RS63244B1 (en) 2011-12-16 2022-06-30 Modernatx Inc Modified mrna compositions
SG11201403416TA (en) 2011-12-21 2014-07-30 Novartis Ag Compositions and methods for antibodies targeting factor p
JP6271441B2 (en) 2012-01-27 2018-01-31 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Compositions and methods for diagnosing and treating diseases associated with neurite degeneration
CN104185681A (en) 2012-02-01 2014-12-03 卡姆普根有限公司 C10RF32 antibodies, and uses thereof for treatment of cancer
SI2814829T1 (en) 2012-02-13 2017-02-28 Bristol-Myers Squibb Company Enediyne compounds, conjugates thereof, and uses and methods therefor
ES2662128T3 (en) 2012-03-05 2018-04-05 Adaptive Biotechnologies Corporation Determination of paired immune receptor chains from the frequency of matching subunits
WO2013138702A2 (en) 2012-03-15 2013-09-19 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2844282T (en) 2012-05-04 2019-07-23 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
RU2631797C2 (en) 2012-05-08 2017-09-26 Эдэптив Байотекнолоджиз Корпорейшн Compositions and methods of measurement and calibration of systematic mistake of amplification in multiplex pcr-reactions
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
CN104470949A (en) 2012-05-15 2015-03-25 百时美施贵宝公司 Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
BR112014032276A2 (en) 2012-06-22 2017-11-28 King S College London vista-ig constructs and the use of vista-ig for the treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
JP6514103B2 (en) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． Dimer protein with triple mutation
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US10034938B2 (en) 2012-08-30 2018-07-31 Amgen Inc. Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
JOP20200308A1 (en) 2012-09-07 2017-06-16 Novartis Ag IL-18 binding molecules
CN105246507B (en) 2012-09-07 2019-01-25 达特茅斯大学理事会 VISTA regulator for diagnosing and treating cancer
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
SG10201608703SA (en) 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
LT2922554T (en) 2012-11-26 2022-06-27 Modernatx, Inc. Terminally modified rna
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
ES2715673T3 (en) 2012-12-03 2019-06-05 Bristol Myers Squibb Co Improvement of the anti-cancer activity of immunomodulatory FC fusion proteins
EA033643B1 (en) 2012-12-05 2019-11-12 Novartis Ag Antibody to erythropoetin or antigen binding fragment thereof
EA201591176A1 (en) 2012-12-18 2016-02-29 Новартис Аг COMPOSITIONS AND METHODS WITH THE USE OF PEPTIDE MARK, CONNECTED WITH HYALURONANE
EP2938633B1 (en) 2012-12-28 2018-02-07 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
MX2015008740A (en) 2013-01-10 2015-10-26 Genmab Bv Human igg1 fc region variants and uses thereof.
CU24300B1 (en) 2013-02-08 2017-12-08 Novartis Ag ANTI-IL-17A ANTIBODIES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
KR102215954B1 (en) 2013-02-14 2021-02-15 브리스톨-마이어스 스큅 컴퍼니 Tubulysin compounds, methods of making and use
PT2961388T (en) 2013-03-01 2019-07-11 Astex Pharmaceuticals Inc Drug combinations
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2014153150A1 (en) * 2013-03-14 2014-09-25 Lee Delphine J Methods of predicting anti ctla-4 response and recurrence of cancer
JP2016514130A (en) 2013-03-14 2016-05-19 ノバルティス アーゲー Antibody against Notch3
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
KR101472903B1 (en) 2013-05-16 2014-12-16 (주)케어젠 Peptides for Inhibiting an Activity of T Lymphocyte and Uses Thereof
WO2014186878A1 (en) 2013-05-24 2014-11-27 Cashman Neil R Cell senescence markers as diagnostic and therapeutic targets
JP6581572B2 (en) 2013-06-07 2019-09-25 デューク ユニバーシティ Complement factor H inhibitor
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
KR102564207B1 (en) 2013-08-08 2023-08-10 싸이튠 파마 IL-15 and IL-15R aplha sushi domain based modulokines
LT3030262T (en) 2013-08-08 2020-03-10 Cytune Pharma Combined pharmaceutical composition
US9777013B2 (en) 2013-08-14 2017-10-03 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
JP2016528247A (en) 2013-08-14 2016-09-15 ノバルティス アーゲー How to treat sporadic inclusion body myositis
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (en) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 Polynucleotides encoding low density lipoprotein receptor
EP3057990B1 (en) 2013-10-18 2019-09-04 Regeneron Pharmaceuticals, Inc. Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
CA2928908C (en) 2013-11-01 2021-01-12 Pfizer Inc. Vectors for expression of prostate-associated antigens
US20150273033A1 (en) 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2920677T3 (en) 2013-12-24 2022-08-08 Janssen Pharmaceutica Nv Anti-VISTA Antibodies and Fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR20220127940A (en) 2014-03-05 2022-09-20 브리스톨-마이어스 스큅 컴퍼니 Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CN104974253A (en) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 Anti-CTLA-4/PD-1 bispecific antibody as well as preparation method and application thereof
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
SI3560954T1 (en) 2014-04-03 2021-11-30 Igm Biosciences, Inc. Modified j-chain
CN106659757B (en) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 Superagonists, partial agonists and antagonists of interleukin 2
TW201622746A (en) 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture
TW201623333A (en) 2014-05-13 2016-07-01 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
JP2017515859A (en) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Treatment of lung cancer using a combination of anti-PD-1 antibodies and other anticancer agents
EP3498295A1 (en) 2014-05-28 2019-06-19 Agenus Inc. Anti-gitr antibodies and methods of use thereof
EP3610924B1 (en) 2014-06-06 2021-11-03 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MX2016016310A (en) 2014-06-11 2017-10-20 A Green Kathy Use of vista agonists and antagonists to suppress or enhance humoral immunity.
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
EP3166688A4 (en) 2014-07-08 2017-12-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
PL3169341T3 (en) 2014-07-16 2019-12-31 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
CA2955084C (en) 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
CN105296433B (en) 2014-08-01 2018-02-09 中山康方生物医药有限公司 A kind of CTLA4 antibody, its medical composition and its use
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
ES2906216T3 (en) 2014-08-07 2022-04-13 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
KR101940430B1 (en) 2014-08-07 2019-01-18 가꼬우호우징 효고 이카다이가쿠 Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
CN106470705B (en) * 2014-08-08 2020-03-31 美国政府(由卫生和人类服务部的部长所代表) Photocontrolled removal of targets in vivo and in vitro
AU2015301753B2 (en) 2014-08-12 2021-04-08 Massachusetts Institute Of Technology Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
RU2718914C2 (en) 2014-09-13 2020-04-15 Новартис Аг Combined treatment methods using alk inhibitors
AU2015318018B2 (en) 2014-09-16 2017-05-11 Synermore Biologics (Suzhou) Co. Ltd. Anti-EGFR antibody and uses of same
MX2017004708A (en) 2014-10-10 2017-10-12 Idera Pharmaceuticals Inc Treatment of cancer using tlr9 agonist with checkpoint inhibitors.
PL3207130T3 (en) 2014-10-14 2020-02-28 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2016069886A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corporation Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10738078B2 (en) 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
CN107249631B (en) 2014-11-07 2021-11-23 十一生物治疗股份有限公司 Improved IL-6 antibodies
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
SI3221346T1 (en) 2014-11-21 2020-11-30 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EA035766B1 (en) 2014-11-21 2020-08-07 Бристол-Майерс Сквибб Компани Antibodies against cd73 and uses thereof
TN2017000223A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
CN107249632A (en) 2014-12-04 2017-10-13 百时美施贵宝公司 Combination for the anti-CS1 and the anti-antibody of PD 1 for the treatment of cancer (myeloma)
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
ES2948037T3 (en) 2014-12-18 2023-08-30 Amgen Inc Frozen Stable Herpes Simplex Virus Formulation
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
CN104479019B (en) * 2014-12-26 2020-07-21 上海复宏汉霖生物技术股份有限公司 anti-CT L A-4 humanized antibody
US10682365B2 (en) 2014-12-31 2020-06-16 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
JP6676058B2 (en) 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
MA41414A (en) 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS
EP3250588A1 (en) 2015-01-29 2017-12-06 Board of Trustees of Michigan State University Cryptic polypeptides and uses thereof
AR103675A1 (en) * 2015-02-13 2017-05-24 Sorrento Therapeutics Inc ANTI-CTLA4 THERAPEUTIC ANTIBODIES
ES2858306T3 (en) 2015-02-24 2021-09-30 Adaptive Biotechnologies Corp Method for determining HLA status by sequencing the immune repertoire
BR112017018365A2 (en) 2015-03-13 2018-04-10 Bristol-Myers Squibb Company use of alkaline washes during chromatography to remove impurities
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
US20180105554A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran sulfate to enhance protein a affinity chromatography
WO2016153983A1 (en) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran for protein purification
PT3273992T (en) 2015-03-23 2020-08-21 Jounce Therapeutics Inc Antibodies to icos
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
CA2979726A1 (en) 2015-04-01 2016-10-06 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
JP6311094B2 (en) 2015-04-07 2018-04-18 サイトリミック株式会社 Medicine
US11215616B2 (en) 2015-04-10 2022-01-04 National Institutes Of Health (Nih), (Dhhs), U.S. Government Methods of determining patient populations amenable to immunomodulatory treatment of cancer
US20160304607A1 (en) 2015-04-17 2016-10-20 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-pd-1 antibody and another antibody
KR101994020B1 (en) 2015-04-20 2019-06-27 미쓰비시덴키 가부시키가이샤 Laser apparatus and extreme ultraviolet light generating device
US10174113B2 (en) 2015-04-28 2019-01-08 Bristol-Myers Squibb Company Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody
KR20170140316A (en) 2015-04-28 2017-12-20 브리스톨-마이어스 스큅 컴퍼니 Treatment of PD-L1-positive melanoma with anti-PD-1 antibody
PL3291679T3 (en) 2015-05-06 2022-04-25 Snipr Technologies Limited Altering microbial populations & modifying microbiota
EP3736287A1 (en) 2015-05-11 2020-11-11 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
EP3297674B1 (en) 2015-05-22 2023-01-04 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
HRP20230060T1 (en) 2015-05-29 2023-03-17 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
AU2016271475A1 (en) 2015-06-03 2017-12-21 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
MX2017015690A (en) 2015-06-05 2018-07-06 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor.
DK3313882T3 (en) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
EP3950065A1 (en) 2015-06-29 2022-02-09 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
CN107922500A (en) 2015-06-29 2018-04-17 洛克菲勒大学 The anti-CD 40 antibodies of agonist activity with enhancing
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10544224B2 (en) 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
CN108136025B (en) 2015-07-16 2022-09-06 比奥克斯塞尔医疗股份有限公司 A novel method of treating cancer using immunomodulation
MX2017016844A (en) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Compositions and methods for treating cancer.
AU2016303489B2 (en) 2015-07-31 2023-02-16 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
JP6940479B2 (en) 2015-08-03 2021-09-29 ノバルティス アーゲー How to treat FGF21-related disorders
US20180222990A1 (en) 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
AU2016306090B2 (en) * 2015-08-11 2019-05-02 Novartis Ag 5-bromo-2,6-di-(1H-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
PT3334761T (en) 2015-08-13 2023-08-17 Univ New York Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
US11385231B2 (en) 2015-08-27 2022-07-12 Inserm (Institut National De La Sante Et De La Recherche Scientifique) Methods for predicting the survival time of patients suffering from a lung cancer
PE20181322A1 (en) 2015-09-01 2018-08-14 Agenus Inc ANTI-PD1 ANTIBODY AND ITS METHODS OF USE
KR102611244B1 (en) 2015-09-03 2023-12-06 오노 야꾸힝 고교 가부시키가이샤 Cancer immunity enhancer by Allergin-1 antagonist
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
RU2638457C2 (en) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
DK3356401T3 (en) 2015-09-30 2020-09-07 Igm Biosciences Inc BINDING MOLECULES WITH MODIFIED J-CHAIN
CN108463245A (en) 2015-09-30 2018-08-28 Igm生物科学有限公司 The binding molecule of J chains with modification
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017070110A1 (en) 2015-10-19 2017-04-27 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
EP3365372A1 (en) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
WO2017079202A1 (en) 2015-11-02 2017-05-11 Board Of Regents, The University Of Texas System Methods of cd40 activation and immune checkpoint blockade
CN108350077A (en) 2015-11-03 2018-07-31 糖模拟物有限公司 Generate monoclonal antibody, the method and composition of candidate stem cell and the method using the antibody and candidate stem cell
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017086419A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
JP2018538263A (en) 2015-11-18 2018-12-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Method for treating lung cancer using a combination of anti-PD-1 antibody and anti-CTLA-4 antibody
EP3383904A4 (en) * 2015-11-19 2019-12-04 Zeling Cai Ctla-4 antibodies and uses thereof
US11213586B2 (en) 2015-11-19 2022-01-04 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)
EP3383920B1 (en) 2015-11-30 2024-01-10 The Regents of the University of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
RU2018123717A (en) 2015-12-01 2020-01-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед COMBINED TREATMENTS, THEIR APPLICATIONS AND METHODS
KR20180083944A (en) 2015-12-02 2018-07-23 아게누스 인코포레이티드 Antibodies and methods for their use
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
TW202208440A (en) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 Bispecific Molecules Having Immunoreactivity with PD-1 and CTLA-4, and Methods of Use Thereof
CN109069623A (en) 2015-12-18 2018-12-21 诺华股份有限公司 Target the antibody and its application method of CD32b
CN108431034A (en) 2015-12-21 2018-08-21 百时美施贵宝公司 The variant antibodies specific conjugated for site-
HRP20220525T1 (en) 2015-12-23 2022-05-27 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
US10052315B2 (en) 2016-01-08 2018-08-21 Celgene Corporation Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
AR107321A1 (en) 2016-01-08 2018-04-18 Celgene Corp ANTIPROLIFERATIVE COMPOUNDS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES
JP7071922B2 (en) 2016-01-08 2022-05-19 セルジーン コーポレイション Solid form of 2- (4-chlorophenyl) -N-((2- (2,6-dioxopiperidine-3-yl) -1-oxoisoindoline-5-yl) methyl) -2,2-difluoroacetamide , And their pharmaceutical compositions and uses
EP3400023A1 (en) * 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
BR112018013967A2 (en) 2016-01-19 2019-02-05 Pfizer cancer vaccines
ES2847155T3 (en) 2016-01-21 2021-08-02 Novartis Ag Multispecific molecules targeting CLL-1
US10822415B2 (en) 2016-01-28 2020-11-03 Inserm (Institut National De La Santéet De La Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
US10918737B2 (en) 2016-01-28 2021-02-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancer
CA3014013A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
US20230183346A1 (en) 2016-02-26 2023-06-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
SG11201806861SA (en) 2016-03-04 2018-09-27 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
US10894835B2 (en) 2016-03-04 2021-01-19 The Rockefeller University Antibodies to CD40 with enhanced agonist activity
JP7208492B2 (en) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド Methods of treating solid tumors or lymphoid tumors with combination therapy
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
JP7137474B2 (en) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド NaPi2b targeting antibody-drug conjugates and methods of use thereof
PT3429618T (en) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
EP3433275A1 (en) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
CN109608443B (en) 2016-04-07 2021-09-07 葛兰素史密斯克莱知识产权发展有限公司 Heterocyclic amides as protein modulators
EA201892128A1 (en) 2016-04-07 2019-04-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед HETEROCYCLIC AMIDES USEFUL AS MODULATORS
MA44776A (en) 2016-04-15 2019-03-06 Immunext Inc HUMAN ANTI-VISTA ANTIBODIES AND THEIR USE
CA3021328A1 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
WO2017189976A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
CA3023678A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
KR20190005924A (en) 2016-05-10 2019-01-16 브리스톨-마이어스 스큅 컴퍼니 Antibody-drug conjugates of tuburicin analogs with improved stability
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
LT3458083T (en) 2016-05-18 2023-02-10 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
JP7194594B2 (en) 2016-05-18 2022-12-22 モデルナティエックス インコーポレイテッド Combinations of mRNAs encoding immunomodulatory polypeptides and uses thereof
MA45037A (en) 2016-05-18 2019-03-27 Modernatx Inc RNAM-BASED POLYTHERAPY FOR CANCER TREATMENT
CN107400166A (en) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 for CTLA4 single domain antibody and its derived protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating agents with immunotherapies to treat cancer
CN109689089A (en) 2016-05-25 2019-04-26 国家医疗保健研究所 The method and composition for the treatment of cancer
WO2017210181A1 (en) 2016-05-30 2017-12-07 Geovax Inc. Compositions and methods for generating an immune response to hepatitis b virus
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
LT3463457T (en) 2016-06-02 2023-09-11 Bristol-Myers Squibb Company Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
ES2897964T3 (en) 2016-06-03 2022-03-03 Bristol Myers Squibb Co Use of anti-PD-1 antibody in the treatment of patients with colorectal cancer
WO2017210631A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
AU2017279029A1 (en) 2016-06-08 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as ATF4 pathway inhibitors
US10851053B2 (en) 2016-06-08 2020-12-01 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3471759A1 (en) 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
JOP20180117B1 (en) 2016-07-12 2022-03-14 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG10201911972QA (en) 2016-07-14 2020-02-27 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
EP3484516A4 (en) 2016-07-14 2020-03-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
EP3487503A1 (en) 2016-07-20 2019-05-29 GlaxoSmithKline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018026663A1 (en) * 2016-08-01 2018-02-08 Ignyta, Inc. Combinations for the treatment of cancer
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
US11649289B2 (en) 2016-08-04 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Anti-ICOS and anti-PD-1 antibody combination therapy
US11878060B2 (en) 2016-08-07 2024-01-23 Novartis Ag mRNA-mediated immunization methods
BR112019002529A2 (en) 2016-08-09 2019-05-28 Kymab Ltd isolated antibody, composition, method for modulating t-cell balance, method for treating a therapy-treatable disease or condition, method for treating cancer, igg1 antibody combination, anti-ics antibody, transgenic non-human mammal, and method for producing a antibody
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
EP3497112A1 (en) 2016-08-12 2019-06-19 Bristol-Myers Squibb Company Methods of purifying proteins
CN109641911B (en) 2016-08-19 2023-02-21 百时美施贵宝公司 seco-cyclopropylpyrroloindole compounds and antibody-drug conjugates thereof and methods of making and using
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018046738A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
US11261233B2 (en) 2016-09-19 2022-03-01 OncoC4, Inc. CD80 and CD86 binding protein compositions and uses thereof
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
JP7305538B2 (en) 2016-09-23 2023-07-10 メルス ナムローゼ フェンノートシャップ Binding molecules that modulate biological activities expressed by cells
EP3518946A4 (en) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
EP3519825A1 (en) 2016-10-03 2019-08-07 Abbott Laboratories Improved methods of assessing gfap status in patient samples
US10618962B2 (en) * 2016-10-10 2020-04-14 Crown Bioscience (Taicang) Inc. Anti-CTLA4 antibodies
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
TW201813664A (en) 2016-10-11 2018-04-16 賽多利克公司 Medicament
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11278592B2 (en) 2016-10-12 2022-03-22 Board Of Regents, The University Of Texas System Methods and compositions for TUSC2 immunotherapy
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
JP7258747B2 (en) 2016-10-28 2023-04-17 ブリストル－マイヤーズ スクイブ カンパニー Method for treating urothelial cancer using anti-PD-1 antibody
PE20191131A1 (en) 2016-11-03 2019-09-02 Bristol Myers Squibb Co ACTIVABLE CYTOTOXIC T LYMPHOCYTE 4 ANTI ANTIGEN (CTLA-4) ANTIBODIES AND THEIR USES
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11672771B2 (en) 2016-11-04 2023-06-13 Aximmune, Inc. Beta-alethine, immune modulators, and uses thereof
WO2018089293A2 (en) * 2016-11-08 2018-05-17 Qilu Puget Sound Biotherapeutics Corporation Anti-pd1 and anti-ctla4 antibodies
US11883430B2 (en) 2016-11-09 2024-01-30 Musc Foundation For Research Development CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
EP3538546A1 (en) 2016-11-14 2019-09-18 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
US20190345500A1 (en) 2016-11-14 2019-11-14 |Nserm (Institut National De La Santé Et De La Recherche Médicale) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
BR112018014281A2 (en) 2016-11-15 2018-12-18 H Lundbeck As agents, uses and methods for the treatment of synucleinopathy
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3544601B1 (en) 2016-11-23 2024-03-20 Translational Drug Development, LLC A composition comprising a benzamide and a tnfrsf agonist binding to 4-1bb or gitr, and the use thereof in the treatment of cancer.
CN106432499A (en) * 2016-11-24 2017-02-22 上海美迪西生物医药股份有限公司 Preparation method of CTLA-4 antibody FAB in insect expression system
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
CA3045241A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
JP2020511407A (en) 2016-12-01 2020-04-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Combination therapy
WO2018106862A1 (en) * 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CA3040924A1 (en) 2016-12-09 2018-06-14 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof
CN110049779A (en) 2016-12-12 2019-07-23 第一三共株式会社 The combination of antibody-drug conjugates and immunologic test point inhibitor
CN110381997A (en) 2016-12-12 2019-10-25 茂体外尔公司 For treating and preventing the method and composition comprising gene-virus therapy and immunologic test point inhibitor of cancer and infectious diseases
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018119380A2 (en) 2016-12-23 2018-06-28 Bristol-Myers Squibb Company Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties
CA3047508A1 (en) 2016-12-23 2018-06-28 Virttu Biologics Limited Treatment of cancer
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
MA47205A (en) 2017-01-04 2019-11-13 H Lundbeck As SPECIFIC ANTIBODIES OF HYPERPHOSPHORYLATED TAU PROTEIN TO TREAT EYE DISEASES
TW201833140A (en) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 Anti-fgfr antibodies and methods of use
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US10434095B2 (en) 2017-01-27 2019-10-08 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
WO2018146128A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
WO2018148381A1 (en) 2017-02-07 2018-08-16 Nantcell, Inc. Maximizing t-cell memory and compositions and methods therefor
WO2018146148A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting the response to checkpoint blockade cancer immunotherapy
IL292067B2 (en) 2017-02-08 2024-01-01 Novartis Ag Fgf21 mimetic antibodies and uses thereof
TWI674261B (en) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 modulators
EA201991720A1 (en) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани ANTIBODIES TO ALPHA-SINUCLEIN AND THEIR APPLICATIONS
BR112019017583A2 (en) 2017-02-24 2020-04-07 Univ Texas assay for detection of pancreatic cancer at an early stage
BR112019017738A2 (en) 2017-02-27 2020-04-07 Glaxosmithkline Ip Dev Ltd combination, pharmaceutical composition, use of a combination or pharmaceutical composition, method for treating cancer in a human, and, compound
TW201834697A (en) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Combination therapies of her2-targeted antibody-drug conjugates
CN116440257A (en) 2017-02-28 2023-07-18 百时美施贵宝公司 Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to vaccine
EP3366703B1 (en) 2017-02-28 2019-04-03 Ralf Kleef Immune checkpoint therapy with hyperthermia
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
US20200150125A1 (en) 2017-03-12 2020-05-14 Yeda Research And Development Co., Ltd. Methods of diagnosing and prognosing cancer
CN110461346A (en) 2017-03-15 2019-11-15 美国安进公司 Oncolytic virus is independent or the purposes for being used for treating cancer is combined with checkpoint inhibitor
CN106916226B (en) * 2017-03-17 2020-01-14 信达生物制药(苏州)有限公司 Application of immunoregulation medicament with CTLA-4 as target spot in treatment of tuberculosis
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
AU2018240117A1 (en) 2017-03-24 2019-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for preventing and treating heart disease
US11359005B2 (en) 2017-03-30 2022-06-14 The Johns Hopkins University Supramolecular high affinity protein-binding system for purification of biomacromolecules
US20210101980A1 (en) 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
US11571459B2 (en) 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
AU2018251987A1 (en) 2017-04-14 2019-12-05 Cg Oncology, Inc. Methods of treating bladder cancer
CN110546513A (en) 2017-04-15 2019-12-06 雅培实验室 Methods for using early biomarkers to aid in hyperacute diagnosis and determination of traumatic brain injury in human subjects
JP2020517737A (en) 2017-04-21 2020-06-18 シルラゼン， インコーポレイテッド Combination therapy of oncolytic vaccinia virus and checkpoint inhibitor
EP3615070A1 (en) 2017-04-26 2020-03-04 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
AU2018256845B2 (en) 2017-04-28 2024-03-14 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
KR102376863B1 (en) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. mesothelin binding protein
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
IL312337A (en) 2017-05-19 2024-06-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
PE20200303A1 (en) 2017-05-24 2020-02-06 Novartis Ag ANTIBODY PROTEINS GRAFTED WITH CYTOKINE AND METHODS OF USE IN THE TREATMENT OF CANCER
SG10201913206RA (en) 2017-05-25 2020-02-27 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions
CN110651190A (en) 2017-05-25 2020-01-03 雅培实验室 Method for using early biomarkers to help determine whether to perform imaging on a human subject who has suffered or may have suffered a head injury
CN110720041B (en) 2017-05-30 2024-04-26 雅培实验室 Methods for aiding diagnosis and assessment of mild traumatic brain injury in human subjects using cardiac troponin I and early biomarkers
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
EP3630842A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
JP2020523018A (en) 2017-06-09 2020-08-06 プロビデンス ヘルス アンド サービシーズ−オレゴン Use of CD39 and CD103 for identification of tumor-reactive human T cells for treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN111201035A (en) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Uses and methods for IL-2 superagonists, agonists, and fusions thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CN111032025A (en) 2017-06-20 2020-04-17 居里研究所 Use of an inhibitor of SUV39H1 histone methyltransferase in the combination therapy of cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
BR112019027402A2 (en) 2017-06-22 2020-07-07 Celgene Corporation treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus
TW201906865A (en) 2017-06-28 2019-02-16 瑞士商諾華公司 Method of preventing and treating urinary incontinence
SG11201913008TA (en) 2017-06-30 2020-01-30 Celgene Corp Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
CN110896634A (en) 2017-07-03 2020-03-20 葛兰素史密斯克莱知识产权发展有限公司 2- (4-chlorophenoxy) -N- ((1- (2- (4-chlorophenoxy) ethynylazetidin-3-yl) methyl) acetamide derivatives and related compounds as ATF4 inhibitors for the treatment of cancer and other diseases
JP2020525513A (en) 2017-07-03 2020-08-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ N-(3-(2-(4-chlorophenoxy)acetamidobicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1 as an ATF4 inhibitor for treating cancer and other diseases -Carboxamide derivatives and related compounds
CN107325181A (en) * 2017-07-05 2017-11-07 无锡傲锐东源生物科技有限公司 Anti-CTLA 4 protein monoclonal antibody and application thereof
AU2018301335B2 (en) 2017-07-10 2022-09-15 Celgene Corporation Antiproliferative compounds and methods of use thereof
RU2020100072A (en) 2017-07-11 2021-08-11 Пфайзер Инк. IMMUNOGENIC COMPOSITIONS CONTAINING CEA, MUC1 AND TERT
AU2018301681B2 (en) 2017-07-14 2022-07-14 Innate Tumor Immunity, Inc. NLRP3 modulators
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
TWI799432B (en) 2017-07-27 2023-04-21 美商再生元醫藥公司 Anti-ctla-4 antibodies and uses thereof
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Indazole derivatives useful as perk inhibitors
JP2020529409A (en) 2017-08-03 2020-10-08 大塚製薬株式会社 Drug compounds and their purification methods
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
JP2020531430A (en) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-CTLA4 probody therapy targeting antibodies
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
EP4364741A3 (en) 2017-08-18 2024-07-03 Cothera Bioscience, Inc. Polymorphic form of tg02
US11745165B2 (en) 2017-08-18 2023-09-05 The Johns Hopkins University Supramolecular filamentous assemblies for protein purification
CN111511762A (en) 2017-08-21 2020-08-07 天演药业公司 anti-CD137 molecules and uses thereof
TW201922721A (en) 2017-09-07 2019-06-16 英商葛蘭素史克智慧財產發展有限公司 Chemical compounds
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2019057744A1 (en) 2017-09-19 2019-03-28 Institut Curie Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
SG11202002282TA (en) 2017-09-20 2020-04-29 Regeneron Pharma Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
TW201927771A (en) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 Heterocyclic amides useful as protein modulators and methods of using the same
BR112020006780A2 (en) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited modulators of the interferon gene stimulator (sting)
CN111465612A (en) 2017-10-13 2020-07-28 哈普恩治疗公司 B cell maturation antigen binding proteins
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company Methods of treating tumor
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
EP3704159A1 (en) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
JP7201400B2 (en) 2017-11-14 2023-01-10 ファイザー・インク EZH2 inhibitor combination therapy
CA3083158A1 (en) 2017-11-24 2019-05-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for treating cancers
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
JP7344801B2 (en) 2017-12-09 2023-09-14 アボット・ラボラトリーズ Glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) Methods to assist in diagnosis and assessment of injuries sustained or potential injuries
JP7379165B2 (en) 2017-12-09 2023-11-14 アボット・ラボラトリーズ Methods for aiding in diagnosing and assessing traumatic brain injury in human subjects using a combination of GFAP and UCH-L1
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
SG11202005692WA (en) 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
WO2019126691A1 (en) 2017-12-21 2019-06-27 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
JP2021510733A (en) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Combination of selective histone deacetylase 3 (HDAC3) inhibitor and immunotherapeutic agent for the treatment of cancer
EP3737696A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019137541A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
WO2019143607A1 (en) 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
CN111629731A (en) 2018-01-22 2020-09-04 百时美施贵宝公司 Compositions and methods for treating cancer
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019160755A1 (en) * 2018-02-13 2019-08-22 Merck Sharp & Dohme Corp. Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies
EP3762105A1 (en) 2018-03-06 2021-01-13 Institut Curie Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
KR20210004966A (en) 2018-03-12 2021-01-13 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Use of calorie-limiting mimetics for enhancing chemo-immunotherapy for cancer treatment
NZ782442A (en) 2018-03-14 2022-01-28 Surface Oncology Inc Antibodies that bind cd39 and uses thereof
CN110272490B (en) * 2018-03-14 2021-05-14 上海开拓者生物医药有限公司 Targeted CTLA-4 antibody, preparation method and application thereof
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
MX2020009786A (en) 2018-03-21 2020-10-12 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH.
JP7351845B2 (en) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Antibodies against MICA and/or MICB and their uses
EP3773685A1 (en) 2018-03-25 2021-02-17 SNIPR Biome ApS. Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
KR20200136417A (en) 2018-03-27 2020-12-07 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Compounds with anti-tumor activity against cancer cells bearing the HER2 exon 19 mutation
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
KR20200136464A (en) 2018-03-29 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 Method for purifying monomeric monoclonal antibodies
KR20200139724A (en) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 How to treat a tumor
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
JOP20200243A1 (en) 2018-04-09 2020-09-29 Eisai R&D Man Co Ltd Pladienolide compounds and their use
SG11202009907XA (en) 2018-04-12 2020-11-27 Eisai R&D Man Co Ltd Pladienolide derivatives as spliceosome targeting agents for treating cancer
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
JP7351850B2 (en) 2018-04-25 2023-09-27 イネイト・テューマー・イミュニティ・インコーポレイテッド NLRP3 modifier
CN112739716A (en) 2018-05-07 2021-04-30 展马博联合股份有限公司 Methods of treating cancer using anti-PD-1 antibodies in combination with anti-tissue factor antibody-drug conjugates
KR20210005617A (en) 2018-05-07 2021-01-14 젠맵 에이/에스 Methods of treating cancer using a combination of anti-PD-1 antibody and anti-tissue factor antibody-drug conjugate
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
SI3796912T1 (en) 2018-05-23 2023-07-31 Celgene Corporation Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
AU2019272751A1 (en) 2018-05-23 2020-12-10 Celgene Corporation Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
BR112020024022A2 (en) 2018-05-29 2021-02-23 Bristol-Myers Squibb Company modified self-adhesive portions for use in prodrugs and conjugates and methods of use and preparation
AR126019A1 (en) 2018-05-30 2023-09-06 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
EP3810109A4 (en) 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
US20210198361A1 (en) 2018-05-31 2021-07-01 Ono Pharmaceutical Co., Ltd. Biomarkers for determining the effectiveness of immune checkpoint inhibitors
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019232449A1 (en) 2018-06-01 2019-12-05 Eisai R&D Management Co., Ltd. Splicing modulator antibody-drug conjugates and methods of use
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
AU2019279012A1 (en) 2018-06-01 2020-12-24 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
CN118108857A (en) 2018-06-01 2024-05-31 利兰斯坦福初级大学董事会 Immune cell targeting constructs
CN112543809A (en) 2018-06-15 2021-03-23 米纳治疗有限公司 Combination therapy comprising C/EBP alpha sarRNA
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US20210253528A1 (en) 2018-07-09 2021-08-19 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
TWI819024B (en) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 Antibodies binding to ilt4
JP7340591B2 (en) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド Genetically engineered immunostimulatory bacterial strains and their uses
CN112638948A (en) 2018-07-11 2021-04-09 戊瑞治疗有限公司 Antibodies that bind to VISTA at acidic pH
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020030634A1 (en) 2018-08-06 2020-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
EP3837015B1 (en) 2018-08-16 2024-02-14 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
KR20210046023A (en) 2018-08-16 2021-04-27 인네이트 튜머 이뮤니티, 인코포레이티드 Imidazo[4,5-c]quinoline-derived NLRP3-modulator
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
WO2020048942A1 (en) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
KR20210089143A (en) 2018-09-18 2021-07-15 메리맥 파마슈티컬즈, 인크. Anti-TNFR2 antibodies and uses thereof
JP2022511337A (en) 2018-09-19 2022-01-31 インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） Methods and Pharmaceutical Compositions for the Treatment of Cancers Resistant to Immune Checkpoint Treatment
SG11202102644XA (en) 2018-09-19 2021-04-29 Alpine Immune Sciences Inc Methods and uses of variant cd80 fusion proteins and related constructs
TWI801664B (en) 2018-09-21 2023-05-11 大陸商信達生物製藥（蘇州）有限公司 Novel interleukin 2 and use thereof
CN112105633B (en) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 Novel interleukin 2 and use thereof
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020068261A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3860578A1 (en) 2018-10-01 2021-08-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
TW202028212A (en) 2018-10-11 2020-08-01 日商小野藥品工業股份有限公司 Sting agonist compound
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
WO2020079164A1 (en) 2018-10-18 2020-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
KR20210081384A (en) 2018-10-23 2021-07-01 브리스톨-마이어스 스큅 컴퍼니 how to treat a tumor
KR20210084546A (en) 2018-10-29 2021-07-07 메르사나 테라퓨틱스, 인코포레이티드 Cysteine Engineered Antibody-Drug Conjugates with Peptide-Containing Linkers
EA202190734A1 (en) 2018-10-30 2021-10-15 Генмаб А/С METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY AGAINST VEGF AND ANTIBODY ANTIBODY AGAINST TISSUE FACTOR-DRUG
NZ775959A (en) * 2018-10-31 2022-08-26 Bioatla Inc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
AU2019379325A1 (en) 2018-11-16 2021-06-03 Genexine, Inc. Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
CN113301899A (en) 2018-11-16 2021-08-24 艾科尔公司 Pharmaceutical combination for the treatment of cancer
BR112021009111A2 (en) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anti-nkg2a antibodies and their uses
EP3883955A1 (en) 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
AU2019385497A1 (en) 2018-11-20 2021-06-17 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
EP3886842A1 (en) 2018-11-26 2021-10-06 Debiopharm International SA Combination treatment of hiv infections
KR20210095868A (en) 2018-11-27 2021-08-03 오노 야꾸힝 고교 가부시키가이샤 Cancer treatment by combination with immune checkpoint inhibitor and polpirinox therapy
EP3887823B1 (en) 2018-11-28 2024-01-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and kit for assaying lytic potential of immune effector cells
EA202191463A1 (en) 2018-11-28 2021-10-13 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем MULTIPLEX EDITING OF THE GENOME OF IMMUNE CELLS TO INCREASE FUNCTIONALITY AND RESISTANCE TO SUPPRESSIVE ENVIRONMENT
US20220106400A1 (en) 2018-11-28 2022-04-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
AU2019386830A1 (en) 2018-11-29 2021-06-24 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
TWI824069B (en) 2018-11-30 2023-12-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 Compounds useful in hiv therapy
KR20210098488A (en) 2018-11-30 2021-08-10 브리스톨-마이어스 스큅 컴퍼니 Antibodies comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses
US20220018835A1 (en) 2018-12-07 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
JP2022511112A (en) 2018-12-11 2022-01-28 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Diazanaphthalene and quinoline derivatives as ALK5 inhibitors
US20220031860A1 (en) 2018-12-12 2022-02-03 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
CN113271981A (en) 2018-12-13 2021-08-17 卫材R&D管理有限公司 Hobertadiene antibody-drug conjugates and methods of use
EP3897624A1 (en) 2018-12-17 2021-10-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of sulconazole as a furin inhibitor
MX2021007639A (en) 2018-12-27 2021-08-11 Amgen Inc Lyophilized virus formulations.
KR20210110838A (en) 2018-12-28 2021-09-09 트랜스진 에스.에이. M2 defective poxvirus
BR112021013157A8 (en) 2019-01-03 2022-12-06 Inst Nat Sante Rech Med USES OF AN NRP-1 INHIBITOR, USE OF A COMBINATION, USE OF A MULTIESPECIFIC ANTIBODY, EX VIVO METHOD TO PREDICT, USE OF AN INHIBITOR, MULTIESPECIFIC ANTIBODY, MODIFIED CELL POPULATION, EX VIVO METHOD OF PRODUCTION AND USE OF A POPULATION OF T CELLS
CA3125756A1 (en) 2019-01-09 2020-07-16 Celgene Corporation Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
CN118178417A (en) 2019-01-09 2024-06-14 细胞基因公司 Antiproliferative compounds and second active agents for the treatment of multiple myeloma
CN113597301A (en) 2019-01-09 2021-11-02 细胞基因公司 Pharmaceutical compositions comprising (S) -4- (4- (4- (((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-4-yl) oxy) methyl) benzyl) piperazin-1-yl) -3-fluorobenzonitrile and methods of using the same
CN113301963A (en) 2019-01-14 2021-08-24 先天肿瘤免疫公司 Substituted quinazolines as NLRP3 modulators for the treatment of cancer
KR20210114983A (en) 2019-01-14 2021-09-24 인네이트 튜머 이뮤니티, 인코포레이티드 NLRP3 modulators
ES2930151T3 (en) 2019-01-14 2022-12-07 Innate Tumor Immunity Inc NLRP3 heterocyclic modulators, for use in cancer treatment
EP3911641A1 (en) 2019-01-14 2021-11-24 Innate Tumor Immunity, Inc. Nlrp3 modulators
SG11202107606VA (en) 2019-01-15 2021-08-30 Inst Nat Sante Rech Med Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
JP7285936B2 (en) 2019-01-22 2023-06-02 ブリストル－マイヤーズ スクイブ カンパニー Antibodies against IL-7R alpha subunit and uses thereof
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
AU2020214412A1 (en) 2019-02-01 2021-08-12 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
US20220281990A1 (en) 2019-03-01 2022-09-08 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
AU2020232264A1 (en) 2019-03-05 2021-08-26 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
EP3946619A1 (en) 2019-03-26 2022-02-09 The Regents Of The University Of Michigan Small molecule degraders of stat3
WO2020198672A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
WO2020205467A1 (en) 2019-03-29 2020-10-08 The Regents Of The University Of Michigan Stat3 protein degraders
CN114126637A (en) 2019-03-29 2022-03-01 居里研究所 Interleukin-2 variants with modified biological activity
US20220042954A1 (en) 2019-03-29 2022-02-10 Bristol-Myers Squibb Company Methods of measuring hydrophobicity of chromatographic resins
TW202102543A (en) 2019-03-29 2021-01-16 美商安進公司 Use of oncolytic viruses in the neoadjuvant therapy of cancer
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020208060A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN114144514A (en) 2019-05-09 2022-03-04 富士胶片细胞动力公司 Method for producing hepatocytes
WO2020232375A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
JP2022533194A (en) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド Benzo [B] [1,8] Diazanaphthalene Acetic Acid Derivatives and Usage
WO2020236562A1 (en) 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
AU2020278465A1 (en) 2019-05-20 2021-12-09 Dana-Farber Cancer Institute, Inc. Boronic ester prodrugs and uses thereof
JP2022534967A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Multiple tumor gene signatures and their uses
KR20220016157A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Cell localization signatures and combination therapies
KR20220016155A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy
MX2021014867A (en) 2019-06-03 2022-03-25 Univ Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants.
JP2022535816A (en) 2019-06-03 2022-08-10 ザ・ユニバーシティ・オブ・シカゴ Methods and compositions for treating cancer using collagen-bound drug carriers
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
WO2020252336A1 (en) 2019-06-12 2020-12-17 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
KR20220020879A (en) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. New IL-15 prodrugs and how to use them
JP2022536419A (en) 2019-06-12 2022-08-16 ヴァンダービルト ユニバーシティー Amino acid transport inhibitor and use thereof
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
JP2022539248A (en) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター Recombinant AD35 vectors and related gene therapy improvements
TWI819225B (en) 2019-07-16 2023-10-21 美國密西根州立大學 Imidazopyrimidines as eed inhibitors and the use thereof
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021014389A1 (en) 2019-07-24 2021-01-28 H. Lundbeck A/S Anti-mglur5 antibodies and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
US11851490B2 (en) 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
CN114641337A (en) 2019-08-27 2022-06-17 密歇根大学董事会 CEREBLON E3 ligase inhibitors
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046293A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
TW202124444A (en) 2019-09-16 2021-07-01 美商表面腫瘤學公司 Anti-cd39 antibody compositions and methods
EP4031531A1 (en) 2019-09-17 2022-07-27 Bial-R&D Investments, S.A. Substituted imidazole carboxamides and their use in the treatment of medical disorders
WO2021055627A1 (en) 2019-09-17 2021-03-25 Bial- Biotech Investments, Inc. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
KR20220100860A (en) 2019-09-17 2022-07-18 비알 - 알&디 인베스트먼츠, 에스.에이. Substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds for use in the treatment of diseases
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (en) 2019-09-18 2021-07-01 瑞士商諾華公司 Combination therapies with entpd2 antibodies
AU2020350689A1 (en) 2019-09-19 2022-03-31 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
AU2020348849A1 (en) 2019-09-19 2022-04-07 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
EP4031873A1 (en) 2019-09-22 2022-07-27 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
EP3798235A1 (en) 2019-09-24 2021-03-31 Industrial Technology Research Institute Anti-tigit antibodies and methods of use
JP2022549854A (en) 2019-09-25 2022-11-29 サーフィス オンコロジー インコーポレイテッド Anti-IL-27 antibody and use thereof
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
US20220363776A1 (en) 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
WO2021080682A1 (en) 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Monoclonal antibodies that bind human cd161 and uses thereof
JPWO2021079958A1 (en) 2019-10-25 2021-04-29
NL2024107B1 (en) 2019-10-26 2021-07-19 Vitroscan B V Compositions for Patient Specific Immunotherapy
NL2024108B1 (en) 2019-10-26 2021-07-19 Vitroscan B V Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
EP4054647A1 (en) 2019-11-04 2022-09-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
AU2020380732A1 (en) 2019-11-07 2022-06-02 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202131954A (en) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
KR20220093349A (en) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 LAG-3 antagonist therapy for melanoma
EP3824954A1 (en) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Device, apparatus and method for minibeam radiation therapy
AU2020385400A1 (en) 2019-11-22 2022-06-09 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
US20220401540A1 (en) 2019-11-27 2022-12-22 Cytlimic Inc. Pharmaceutical composition
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
US20230089255A1 (en) 2019-12-19 2023-03-23 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
IL294226A (en) 2019-12-27 2022-08-01 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
MX2022008412A (en) 2020-01-07 2022-08-08 Univ Texas Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy.
US20230348458A1 (en) 2020-01-10 2023-11-02 Innate Tumor Immunity, Inc. Nlrp3 modulators
CA3167689A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
US20230093147A1 (en) 2020-03-09 2023-03-23 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
CN115485302A (en) 2020-03-09 2022-12-16 百时美施贵宝公司 Antibodies against CD40 with enhanced agonist activity
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
TW202204339A (en) 2020-03-31 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 Substituted pyrimidines and methods of use
JPWO2021205631A1 (en) 2020-04-10 2021-10-14
KR20220167275A (en) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 cancer treatment methods
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
WO2021216670A1 (en) 2020-04-21 2021-10-28 University Of Rochester Inhibitors of human epididymus protein 4
BR112022021020A2 (en) 2020-04-22 2023-02-14 Iovance Biotherapeutics Inc METHOD OF MANUFACTURING A CELL THERAPY PRODUCT, METHODS OF TREATMENT OF THE PATIENT WITH THE EXPANSION AND MANUFACTURED CELL THERAPY PRODUCT, AND, METHOD OF MANUFACTURING A CELL THERAPY PRODUCT
JP2023523794A (en) 2020-05-01 2023-06-07 ノバルティス アーゲー engineered immunoglobulin
JP2023523760A (en) 2020-05-01 2023-06-07 ノバルティス アーゲー immunoglobulin variant
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
CA3182333A1 (en) 2020-05-20 2021-11-25 Institut Curie Single domain antibodies and their use in cancer therapies
EP4153301A2 (en) 2020-05-21 2023-03-29 Board of Regents, The University of Texas System T cell receptors with vgll1 specificity and uses thereof
CN115803343A (en) * 2020-05-26 2023-03-14 百奥泰生物制药股份有限公司 Multispecific antibodies and uses thereof
EP4157319A1 (en) 2020-05-28 2023-04-05 Modernatx, Inc. Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
CA3180060A1 (en) 2020-05-29 2021-12-02 Zongmin ZHAO Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
JP2023528071A (en) 2020-06-03 2023-07-03 エムヴィ バイオセラピューティクス エスエー Combination of ATP hydrolase and immune checkpoint modulator, and use thereof
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
US20210387983A1 (en) 2020-06-10 2021-12-16 Theravance Biopharma R&D Ip, Llc Crystalline alk5 inhibitors and uses thereof
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
BR112022026090A2 (en) 2020-06-25 2023-01-17 Celgene Corp METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES
MX2022015375A (en) 2020-06-29 2023-01-16 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
KR20230033647A (en) 2020-06-30 2023-03-08 멘두스 비.브이. Use of leukemia-derived cells in ovarian cancer vaccines
US20230266322A1 (en) 2020-06-30 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
WO2022002873A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
WO2022010854A1 (en) 2020-07-07 2022-01-13 Celgene Corporation Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
MX2023000197A (en) 2020-07-07 2023-02-22 BioNTech SE Therapeutic rna for hpv-positive cancer.
EP4178678A1 (en) 2020-07-07 2023-05-17 Cancure, LLC Mic antibodies and binding agents and methods of using the same
WO2022011205A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Androgen receptor protein degraders
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
CA3186108A1 (en) 2020-07-21 2022-01-27 Zhiwei Pan Anti-ctla-4 antibody and use thereof
US20230295146A1 (en) 2020-07-24 2023-09-21 The University Of Rochester Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
KR20230042301A (en) 2020-08-04 2023-03-28 애벗트 라보라토리이즈 Improved methods and kits for detecting SARS-COV-2 proteins in samples
JP2023536737A (en) 2020-08-04 2023-08-29 アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー Assays for detecting SARS-COV-2
CA3188728A1 (en) 2020-08-07 2022-02-10 Marc Nasoff Immunoconjugates targeting cd46 and methods of use thereof
US20230265188A1 (en) 2020-08-28 2023-08-24 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
WO2022084325A1 (en) 2020-10-20 2022-04-28 Institut Curie Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2022096604A1 (en) 2020-11-04 2022-05-12 Heidelberg Pharma Research Gmbh Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
AU2021376218A1 (en) 2020-11-08 2023-06-15 Seagen Inc. Combination Therapy
WO2022102731A1 (en) 2020-11-13 2022-05-19 小野薬品工業株式会社 Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4247849A2 (en) 2020-11-17 2023-09-27 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
WO2022106505A1 (en) 2020-11-18 2022-05-27 Institut Curie Dimers of biguanidines and their therapeutic uses
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
US20220170948A1 (en) 2020-12-01 2022-06-02 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
EP4256067A2 (en) 2020-12-04 2023-10-11 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US20240052042A1 (en) 2020-12-14 2024-02-15 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
WO2022136647A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
JP2024504923A (en) 2021-01-11 2024-02-02 シンセカイン インコーポレイテッド Compositions and methods for receptor pairing
IL304031A (en) 2021-01-14 2023-08-01 Inst Curie Her2 single domain antibodies variants and cars thereof
CN117529338A (en) 2021-01-19 2024-02-06 威廉马歇莱思大学 Bone-specific delivery of polypeptides
EP4281187A1 (en) 2021-01-20 2023-11-29 Bioentre LLC Ctla4-binding proteins and methods of treating cancer
JP2024506249A (en) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ Methods of tumor vaccination
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US20240190874A1 (en) 2021-03-03 2024-06-13 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4070799A1 (en) 2021-04-08 2022-10-12 Nuvamid SA Compositions for the improvement of sport performance
JP2024518709A (en) 2021-04-10 2024-05-02 プロファウンドバイオ ユーエス カンパニー FOLR1-BINDING AGENTS, CONJUGATS THEREOF AND METHODS OF USING SAME
EP4079311A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
EP4079310A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
AU2022262644A1 (en) 2021-04-23 2023-11-09 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
WO2022229644A1 (en) 2021-04-28 2022-11-03 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
US20220381796A1 (en) 2021-05-18 2022-12-01 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
JPWO2022260132A1 (en) 2021-06-10 2022-12-15
US20240118279A1 (en) 2021-06-14 2024-04-11 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
CN117616123A (en) 2021-06-25 2024-02-27 中外制药株式会社 anti-CTLA-4 antibodies
WO2022270612A1 (en) 2021-06-25 2022-12-29 中外製薬株式会社 Use of anti-ctla-4 antibody
EP4367269A1 (en) 2021-07-05 2024-05-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023014922A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
EP4380682A1 (en) 2021-08-05 2024-06-12 Institut Curie Scanning dynamic device for minibeams production
WO2023028501A1 (en) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
IL311790A (en) 2021-10-05 2024-05-01 Chang Hao Ming Natural killer cells and methods of use thereof
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
AR127408A1 (en) 2021-10-20 2024-01-17 Takeda Pharmaceuticals Co COMPOSITIONS AIMED AT BCMA AND METHODS OF USE THEREOF
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
WO2023077034A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing immune cells
WO2023076989A1 (en) 2021-10-29 2023-05-04 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
CN113907045B (en) * 2021-11-09 2023-01-06 派生特（福州）生物科技有限公司 Method for breeding new strain of pigs and application thereof
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
CA3238167A1 (en) 2021-11-19 2023-05-25 Maria Leia Smith Gpc3 binding agents, conjugates thereof and methods of using the same
CA3238936A1 (en) * 2021-11-24 2023-06-01 Wayne A. Marasco Antibodies against ctla-4 and methods of use thereof
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
CA3240822A1 (en) 2021-12-17 2023-06-22 Tony Lee Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
WO2023161453A1 (en) 2022-02-24 2023-08-31 Amazentis Sa Uses of urolithins
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023180552A1 (en) 2022-03-24 2023-09-28 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023194608A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2023196988A1 (en) 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
WO2023194607A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
TW202400658A (en) 2022-04-26 2024-01-01 瑞士商諾華公司 Multispecific antibodies targeting il-13 and il-18
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
TW202408583A (en) 2022-05-06 2024-03-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
CN117618555A (en) * 2022-08-31 2024-03-01 百奥泰生物制药股份有限公司 Use of anti-TIGIT antibodies in combination with anti-CTLA-4 antibodies for the treatment of tumors
WO2024052356A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024068617A1 (en) 2022-09-26 2024-04-04 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
WO2024084013A1 (en) 2022-10-20 2024-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination therapy for the treatment of cancer
WO2024086827A2 (en) 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
US20240165257A1 (en) 2022-11-01 2024-05-23 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3708238A1 (en) 1987-03-16 1988-09-29 Motoren Werke Mannheim Ag POWER AND HEAT COUPLING SYSTEM
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
ES2125854T3 (en) 1989-08-09 1999-03-16 Rhomed Inc DIRECT RADIO LABELING OF ANTIBODIES AND OTHER PROTEINS WITH TECNETIO OR RENIUM.
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2110518C (en) 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE208374T1 (en) 1992-02-18 2001-11-15 Otsuka Kagaku Kk BETA-LACTAM AND CEPHAM COMPOUNDS AND THEIR PRODUCTION
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
ATE193301T1 (en) 1993-03-09 2000-06-15 Genzyme Corp METHOD FOR ISOLATION OF PROTEINS FROM MILK
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994029444A1 (en) 1993-06-04 1994-12-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for treating kaposi's sarcoma with antisense oligonucleotides
AU7326594A (en) 1993-07-09 1995-02-06 Synergen, Inc. Recombinant ctla4 polypeptides and methods for making the same
JPH09500788A (en) 1993-07-26 1997-01-28 ダナ・ファーバー・キャンサー・インスティテュート・インコーポレイテッド B7-2: CTLA4 / CD28 counter receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2185027A1 (en) 1994-03-08 1995-09-14 Vassiliki A. Boussiotis Methods for modulating t cell unresponsiveness
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
EP0804604A2 (en) 1995-01-20 1997-11-05 Cell Genesys, Inc. Method to improve screening efficiency in fused cells
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
EP1978033A3 (en) * 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5618912A (en) * 1995-05-04 1997-04-08 Pennzoil Products Company Tire sealer and inflator compositions
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ATE352613T1 (en) 1995-08-29 2007-02-15 Kirin Brewery CHIMERIC ANIMAL AND METHOD OF PRODUCING SAME
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (en) 1996-12-03 2009-01-28 アムジェン フレモント インク． Transgenic mammal having human Ig locus comprising a plurality of V {lower H} and V {lower κ} regions, and antibodies produced therefrom
EP0972445B1 (en) * 1997-02-28 2006-07-05 Kirin Beer Kabushiki Kaisha Chimeric mice that express a human antibody
JP2001523958A (en) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド CTLA-4 binding peptides for immunotherapy
WO1998046996A2 (en) 1997-04-11 1998-10-22 The John P. Robarts Research Institute Lck serine phosphorylation assay for t-cell activation and activation-induced cell death
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2205680A1 (en) 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
US6509057B2 (en) 1998-04-01 2003-01-21 Sumitomo Osaka Cement, Co., Ltd. Antibacterial, antifungal or antialgal article and process for producing same
CA2241621A1 (en) 1998-06-26 1999-12-26 National Silicates Ltd. A lubricating method for silicate drilling fluids
DE69938871D1 (en) * 1998-12-03 2008-07-17 Univ California Stimulating T cells against self antigens using CTLA-4 inhibiting agents
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CZ303703B6 (en) * 1998-12-23 2013-03-20 Pfizer Inc. Monoclonal antibody or fragment-binding antigen thereof, pharmaceutical composition in which the antibody or fragment is comprised, a cell line producing the antibody or fragment, process for preparing the antibody, isolated nucleic acid encoding hea
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1792991A1 (en) * 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
US9169311B2 (en) 2013-03-15 2015-10-27 Applied Food Biotechnology, Inc. Feline bitter taste receptors and methods
KR102264548B1 (en) 2014-11-21 2021-06-16 삼성전자주식회사 Semiconductor packages and fabrication method thereof

Also Published As

Publication number Publication date
AU2009202447B2 (en) 2011-11-24
KR100942863B1 (en) 2010-02-17
FR12C0004I2 (en) 2013-01-11
CN102766210A (en) 2012-11-07
FR12C0004I1 (en) 2012-02-24
ATE354655T1 (en) 2007-03-15
WO2001014424A3 (en) 2001-09-20
DE60033530D1 (en) 2007-04-05
EP2829609A1 (en) 2015-01-28
DE60033530T2 (en) 2007-10-31
EP1212422B1 (en) 2007-02-21
AU784012B2 (en) 2006-01-12
PT1212422E (en) 2007-04-30
EP1212422A2 (en) 2002-06-12
CA2381770A1 (en) 2001-03-01
JP5599158B2 (en) 2014-10-01
DE122012000001I1 (en) 2012-03-15
EP3214175A1 (en) 2017-09-06
AU2006201520B2 (en) 2009-03-19
CA2381770C (en) 2007-08-07
DK1212422T3 (en) 2007-07-02
KR100996759B1 (en) 2010-11-25
EP1792991A1 (en) 2007-06-06
CY2012002I2 (en) 2020-05-29
KR20060100950A (en) 2006-09-21
AU2006201520A1 (en) 2006-05-11
IL148079A (en) 2008-04-13
JP2006151993A (en) 2006-06-15
IL189629A0 (en) 2008-06-05
AU2006201520B9 (en) 2009-08-27
CN1371416B (en) 2012-10-10
CN1371416A (en) 2002-09-25
JP2009213478A (en) 2009-09-24
US6984720B1 (en) 2006-01-10
JP2004512005A (en) 2004-04-22
KR20020047132A (en) 2002-06-21
CY1107628T1 (en) 2013-04-18
LU91928I2 (en) 2012-03-09
AU2009202447A1 (en) 2009-07-09
JP4093757B2 (en) 2008-06-04
HK1048831A1 (en) 2003-04-17
JP2012100674A (en) 2012-05-31
MXPA02001911A (en) 2003-07-21
CY2012002I1 (en) 2016-12-14
NZ517202A (en) 2004-05-28
ZA200201190B (en) 2003-05-28
AU7073200A (en) 2001-03-19
KR20090036598A (en) 2009-04-14
WO2001014424A2 (en) 2001-03-01
ES2282133T3 (en) 2007-10-16
CN102766210B (en) 2015-07-08
IL148079A0 (en) 2002-09-12
CA2589418A1 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
FR12C0004I1 (en)
NL300433I1 (en) Methods and compositions for the treatment of glomerulonephritis
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
DK1187632T3 (en) Treatment with anti-ErbB2 antibodies
EP1354034B8 (en) Transgenic transchromosomal rodents for making human antibodies
DE60023043D1 (en) (S, S) reboxetine for the treatment of incontinence
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
PL328858A1 (en) Immunogenous peptides
GEP20105118B (en) Anti-vegf antibodies
SG157951A1 (en) Cripto blocking antibodies and uses thereof
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
YU68602A (en) Monoclonal antibodies to the human ldl receptor, their production and use
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
NO20005548D0 (en) Mykobakterieinhibitorer
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
GB9715177D0 (en) Medicament
ZA989313B (en) Novel compounds for treating diseases associated with the biological effect of endothelin.